Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma.
The relative contraindication of hormonal therapy for patients with prostate cancer and a history of meningioma has not been widely emphasized. Using immunohistochemistry to determine the presence of hormone receptors in meningioma specimens proved potentially valuable in 2 patients with biochemical recurrence after prostatectomy who were being considered for androgen deprivation therapy. These cases also highlight the need for caution against assuming that skull-based intracranial growths in patients receiving hormonal therapy for prostate cancer are metastatic lesions rather than hormonally induced primary tumors.
Lee
Keith L
KL
Department of Urology, Stanford University Medical Center, Stanford, California, USA.
Terris
Martha K
MK
D000368:Aged; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects* / Q000819:agonists* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008577:Meningeal Neoplasms / Q000139:chemically induced* / Q000532:radiotherapy / Q000601:surgery; D008579:Meningioma / Q000139:chemically induced* / Q000532:radiotherapy / Q000601:surgery; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000139:chemically induced / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery
D007987:Gonadotropin-Releasing Hormone